Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lemonade Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.03 (market cap $39.89B), while Lemonade Inc trades at $70.47 (market cap $5.42B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.4× Lemonade Inc's market cap, and Lemonade Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | LMND | |
|---|---|---|
Market Cap | $39.89B | $5.42B |
Sector | Health | Financials |
52-Week High | $491.22 | $96.57 |
52-Week Low | $278.09 | $36.28 |
Enterprise Value | $38.15B | $5.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Lemonade (LMND) trades at $70.51, up 0.26% today, with a bullish technical signal from moving averages and strong support at $69. The company shows accelerating revenue growth, with 2025 revenue reaching $738 million, while narrowing net losses to -$166 million. Recent news highlights expansion into new states and reinsurance program improvements, though the stock faces a mixed analyst consensus with 33% buy ratings.
Outlook remains speculative given persistent losses but improving margins; key opportunities include AI-driven growth and market expansion, while risks involve high valuation multiples and profitability timeline uncertainty. The consensus price target of $67 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
